||A major contributor to this article appears to have a close connection with its subject. (August 2010)|
||This article appears to be written like an advertisement. (August 2010)|
bioMérieux (Euronext: BIM) is a multinational biotechnology company founded and headquartered in France. A subsidiary of Institut Mérieux, bioMérieux is listed on the NYSE Euronext Paris stock exchange.
The company specializes in the field of in vitro diagnostics for the medical and industrial sectors. The group designs, develops, and produces a wide range of diagnosis systems for medicine and industry. It provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Their products are used for diagnosing infectious diseases and providing medical test results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux has revenues of approximate €1.6 billion as of 2013 with 85% of sales occurring outside of France.
- Alain Mérieux founded the company in 1963.
- Institut Mérieux, which belongs to the Mérieux family, is the main shareholder of bioMérieux.